RNA標的低分子創薬市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、エンドユーザー別、地域別、競合別、2020-2030年

世界のRNA標的低分子創薬市場は、2024年に16億8,000万米ドルと評価され、2030年には55億2,000万米ドルに達し、CAGR 21.93％で成長すると予測されています。

この成長の原動力は、がん、神経疾患、遺伝性疾患など幅広い疾患に対応可能なRNA標的低分子医薬品に対する需要の高まりです。RNA標的創薬手法の革新とRNA研究に対する政府の支援強化がこの分野の開発を加速しており、製薬業界全体で多額の投資と関心を集めています。

市場促進要因

RNA生物学と創薬技術の進歩

主な市場課題

RNA構造の複雑さと標的特異性

主要市場動向

創薬における人工知能の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のRNA標的低分子創薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（がん、感染症、代謝性疾患、神経疾患、その他）
  • エンドユーザー別（製薬・バイオ医薬品企業、学術調査機関、その他）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 市場マップ
• 適応症別
• エンドユーザー別
• 地域別

第6章 北米のRNA標的低分子創薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のRNA標的低分子創薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のRNA標的低分子創薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のRNA標的低分子創薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのRNA標的低分子創薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界のRNA標的低分子創薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• AstraZeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F.Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

The Global RNA Targeting Small Molecule Drug Discovery Market, valued at USD 1.68 billion in 2024, is projected to reach USD 5.52 billion by 2030, growing at a CAGR of 21.93%. This growth is fueled by the increasing demand for RNA-targeted small molecule drugs capable of addressing a wide range of conditions, including cancer, neurological, and genetic disorders. Innovations in RNA-targeted drug discovery methods and heightened government support for RNA research are accelerating development in this field, attracting significant investments and interest across the pharmaceutical industry.

Key Market Drivers

Advancements in RNA Biology and Drug Discovery Technologies

Recent developments in RNA biology have revealed new RNA structures and functionalities as viable therapeutic targets. Tools like high-throughput sequencing and gene editing have significantly advanced the discovery of novel RNA targets and the creation of small molecules that can regulate RNA activity. These technological strides are streamlining drug development, making therapies more precise and effective. Moreover, the integration of computational methods and artificial intelligence is improving the prediction of RNA structures and interactions, thereby enhancing the efficiency of the discovery process. These advancements are driving increased pharmaceutical investment in RNA-targeted therapy.

Key Market Challenges

Complexity of RNA Structures and Target Specificity

Designing small molecules to selectively bind RNA targets is inherently challenging due to the intricate secondary and tertiary structures of RNA molecules. Precision is vital to prevent unintended interactions with non-target RNAs, which could cause adverse effects. The flexible nature of RNA adds another layer of difficulty in identifying stable and effective binding sites. Overcoming these hurdles necessitates sophisticated structural analysis tools and innovative drug development strategies, which demand substantial time and resources.

Key Market Trends

Integration of Artificial Intelligence in Drug Discovery

Artificial Intelligence (AI) is playing a transformative role in the discovery of RNA-targeted small molecules. AI technologies are capable of analyzing large datasets to forecast RNA structures, locate potential binding regions, and simulate molecular behavior, which greatly accelerates candidate identification. This not only improves the precision and efficiency of development but also cuts down the time and expense compared to traditional methods. As AI tools continue to evolve, their contribution to RNA-based therapeutic discovery is expected to grow, paving new pathways for drug development.

Key Market Players

• Accent Therapeutics, Inc.
• Anima Biotech Inc.
• Arrakis Therapeutics, Inc.
• AstraZeneca Plc
• Epics Therapeutics, Inc.
• Expansion Therapeutics, Inc.
• F. Hoffmann-La Roche AG
• H3 Biomedicine Inc.
• PTC Therapeutics, Inc.
• Ribometrix, Inc.

Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication:

• Cancer
• Infectious Diseases
• Metabolic Diseases
• Neurological Diseases
• Other

RNA Targeting Small Molecule Drug Discovery Market, By End Users:

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

RNA Targeting Small Molecule Drug Discovery Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.4. By Company (2024)
• 5.3. Market Map
• 5.3.1 By Indication
• 5.3.2 By End Users
• 5.3.3 By Region

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By End User

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By End User

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By End User
  • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By End User

9. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By End User

10. Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
  • 10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Accent Therapeutics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Anima Biotech Inc.
• 15.3. Arrakis Therapeutics, Inc.
• 15.4. AstraZeneca Plc
• 15.5. Epics Therapeutics, Inc.
• 15.6. Expansion Therapeutics, Inc.
• 15.7. F.Hoffmann-La Roche AG
• 15.8. H3 Biomedicine Inc.
• 15.9. PTC Therapeutics, Inc.
• 15.10. Ribometrix, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer